<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Monogenic causes of steroid-resistant nephrotic syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Monogenic causes of steroid-resistant nephrotic syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Monogenic causes of steroid-resistant nephrotic syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="30%"></colgroup><colgroup width="10%"></colgroup> <tbody> <tr> <td class="subtitle1">Gene</td> <td class="subtitle1">Gene product or protein</td> <td class="subtitle1">Kidney histology</td> <td class="subtitle1">Additional notes or associated extrarenal features</td> <td class="subtitle1">OMIM phenotype</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Autosomal recessive</td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/602716" target="_blank">NPHS1</a></em></td> <td>Nephrin</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/256300" target="_blank">#256300</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/604766" target="_blank">NPHS2</a></em></td> <td>Podocin</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/600995" target="_blank">#600995</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/608414" target="_blank">PLCE1</a></em></td> <td>Phospholipase C, epsilon1</td> <td>FSGS or DMS</td> <td> </td> <td><a href="https://www.omim.org/entry/610725" target="_blank">#610725</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/604241" target="_blank">CD2AP</a></em></td> <td>CD2-associated protein</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/607832" target="_blank">#607832</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/600579" target="_blank">PTPRO</a></em></td> <td>Protein-tyrosine phosphatase receptor-type O (or glomerular epithelial protein 1/GLEPP1)</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/614196" target="_blank">#614196</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/601440" target="_blank">DGKE</a></em></td> <td>Diacylglycerol kinase-epsilon</td> <td>MPGN<sup>[1]</sup></td> <td>Atypical hemolytic uremic syndrome</td> <td><a href="https://www.omim.org/entry/615008" target="_blank">#615008</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/602334" target="_blank">EMP2</a></em></td> <td>Epithelial membrane protein-2, which regulates caveolin-1 in kidney</td> <td>n/a</td> <td>Few case reports<sup>[2]</sup></td> <td><a href="https://www.omim.org/entry/615861" target="_blank">#615861</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/601479" target="_blank">MYO1E</a></em></td> <td>Myosin 1E</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/614131" target="_blank">#614131</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/612014" target="_blank">TTC21B</a></em></td> <td>Intraflagellar transport protein 139</td> <td>FSGS</td> <td>Ciliary dysfunction; causes nephronophthisis</td> <td><a href="https://www.omim.org/entry/613820" target="_blank">#613820</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/609720" target="_blank">CRB2</a></em></td> <td>Crumbs homolog 2 protein</td> <td>FSGS, congenital nephrotic syndrome</td> <td>Renal microcysts and cerebral ventriculomegaly</td> <td><a href="https://www.omim.org/entry/616220" target="_blank">#616220</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/602997" target="_blank">CUBN</a></em></td> <td>Cubilin</td> <td>Renal histology not described</td> <td>Might be associated with megaloblastic anemia, because cubilin facilitates intestinal absorption of the vitamin B12 or intrinsic factor complex</td> <td><a href="https://www.omim.org/entry/618884" target="_blank">#618884</a><br/> <a href="https://www.omim.org/entry/261100" target="_blank">#261100</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/606382" target="_blank">MAGI2</a></em></td> <td>Membrane-associated guanylate kinase; multiprotein complex associated with podocytes</td> <td>FSGS</td> <td>Congenital nephrotic syndrome<sup>[3]</sup></td> <td><a href="https://www.omim.org/entry/617609" target="_blank">#617609</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/170285" target="_blank">NUP85</a></em><br/> <em><a href="https://www.omim.org/entry/614351" target="_blank">NUP93</a></em><br/> <em><a href="https://www.omim.org/entry/607617" target="_blank">NUP107</a></em><br/> <em><a href="https://www.omim.org/entry/607613" target="_blank">NUP133</a></em><br/> <em><a href="https://www.omim.org/entry/607614" target="_blank">NUP160</a></em><br/> <em><a href="https://www.omim.org/entry/614352" target="_blank">NUP205</a></em><br/> <em><a href="https://www.omim.org/entry/607845#0001" target="_blank">XP05</a></em></td> <td>Nuclear pore complex: nucleoporins 85 kDa, 93 kDa, 107 kDa, 133 kDa, 160 kDa, 205 kDa, and nuclear export protein exportin 5 (interacts with nucleoporins)</td> <td>FSGS or DMS</td> <td> <p>Nucleoporins mediate transport of proteins or RNA from cell cytoplasm to nucleus.</p> SRNS with ESRD in childhood<sup>[4,5]</sup>; might have partial response to cyclosporine.</td> <td><a href="https://www.omim.org/entry/618176" target="_blank">#618176</a><br/> <a href="https://www.omim.org/entry/616892" target="_blank">#616892</a><br/> <a href="https://www.omim.org/entry/616730" target="_blank">#616730</a><br/> <a href="https://www.omim.org/entry/618177" target="_blank">#618177</a><br/> <a href="https://www.omim.org/entry/618178" target="_blank">#618178</a><br/> <a href="https://www.omim.org/entry/616893" target="_blank">#616893</a></td> </tr> <tr> <td class="subtitle2_left" colspan="5">Autosomal dominant</td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/604638" target="_blank">ACTN4</a></em></td> <td>Actinin-alpha-4</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/603278" target="_blank">#603278</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/603652" target="_blank">TRPC6</a></em></td> <td>Transient receptor potential cation channel, subfamily C, member 6</td> <td>FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/603965" target="_blank">#603965</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/610982" target="_blank">INF2</a></em></td> <td>Inverted formin 2</td> <td>FSGS</td> <td>Variants in <em>INF2</em> also may cause a form of Charcot-Marie-Tooth disease</td> <td><a href="https://www.omim.org/entry/613237" target="_blank">#613237</a><br/> </td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/610586" target="_blank">ARHGAP24</a></em></td> <td>Rho-GTPase-activating protein 24</td> <td>FSGS</td> <td> </td> <td> </td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/616027" target="_blank">ANLN</a></em></td> <td>Anillin</td> <td>FSGS</td> <td>Childhood or adult onset</td> <td><a href="https://www.omim.org/entry/616032" target="_blank">#616032</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/167409" target="_blank">PAX2</a></em></td> <td>Paired box protein 2</td> <td>FSGS</td> <td>May include renal hypoplasia and optic nerve coloboma</td> <td><a href="https://www.omim.org/entry/616002" target="_blank">#636002</a><br/> <a href="https://www.omim.org/entry/120330" target="_blank">#120330</a></td> </tr> <tr> <td class="subtitle2_left" colspan="5">Syndromic forms of nephrotic syndrome</td> </tr> <tr> <td class="indent1" rowspan="3"><em><a href="https://www.omim.org/entry/607102" target="_blank">WT1</a></em> (AD)</td> <td rowspan="3">Wilms tumor protein</td> <td>Denys-Drash syndrome – DMS</td> <td>Early nephrotic syndrome with diffuse mesangial sclerosis; 46XY children have gonadal dysgenesis and atypical or female-appearing external genitalia (male pseudohermaphroditism), Wilms tumor, gonadoblastoma</td> <td><a href="https://www.omim.org/entry/194080" target="_blank">#194080</a></td> </tr> <tr> <td>Frasier syndrome – FSGS</td> <td>SRNS; 46XY children have gonadal dysgenesis and atypical or female-appearing external genitalia (male pseudohermaphroditism), gonadoblastoma risk</td> <td><a href="https://www.omim.org/entry/136680" target="_blank">#136680</a></td> </tr> <tr> <td>Nephrotic syndrome – FSGS</td> <td> </td> <td><a href="https://www.omim.org/entry/256370" target="_blank">#256370</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/150325" target="_blank">LAMB2</a></em> (AR)</td> <td>Laminin subunit beta-2</td> <td>DMS</td> <td>Pierson syndrome – Congenital nephrotic syndrome, DMS, microcoria and buphthalmos, severe neurodevelopmental delay</td> <td><a href="https://www.omim.org/entry/614199" target="_blank">#614199</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/602575" target="_blank">LMX1B</a></em> (AD)</td> <td>LIM homeobox transcription factor 1-beta</td> <td>FSGS</td> <td>Nail-patella syndrome – Absent or displaced patella, absent or pitted nails, small nails, hematuria, proteinuria, nephrotic syndrome in 10 to 15% (SRNS)</td> <td><a href="https://www.omim.org/entry/256020" target="_blank">#256020</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/606622" target="_blank">SMARCAL1</a></em> (AR)</td> <td>Swi/Snf-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein</td> <td>FSGS</td> <td>Schimke immuno-osseous dysplasia – Short stature, spondyloepiphyseal dysplasia, SRNS, kidney failure, T cell immunodeficiency, lentigines, abnormal dentition, thin hair, corneal opacities, arteriosclerosis, headache, cerebral infarcts</td> <td><a href="https://www.omim.org/entry/242900" target="_blank">#242900</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/602257" target="_blank">SCARB2</a></em> (AR)</td> <td>Scavenger receptor class B member 2</td> <td>FSGS</td> <td>Action myoclonus-renal failure syndrome – FSGS, kidney failure, fine tremor, progressive myoclonus epilepsy</td> <td><a href="https://www.omim.org/entry/254900" target="_blank">#254900</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/616144" target="_blank">WDR73</a></em> (AR)</td> <td>WD repeat containing protein 73</td> <td>FSGS (collapsing) or DMS</td> <td>Galloway-Mowat syndrome – Microcephaly, gyral abnormalities (polymicrogyria), hypotonia, seizures, developmental delay, hiatus hernia, kidney failure</td> <td><a href="https://www.omim.org/entry/251300" target="_blank">#251300</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/160775" target="_blank">MYH9</a></em> (AD)</td> <td>Nonmuscle myosin heavy-chain IIA</td> <td>FSGS</td> <td> <p>May-Hegglin – Giant platelets, thrombocytopenia</p> <p>Fechtner – Sensorineural deafness, cataracts, giant platelets, thrombocytopenia, kidney failure in 28%</p> Epstein – Sensorineural deafness, giant platelets, thrombocytopenia, nephritis</td> <td><a href="https://www.omim.org/entry/155100" target="_blank">#155100</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/605025" target="_blank">ITGA3</a></em> (AR)</td> <td>Integrin alpha-3 subunit</td> <td>FSGS</td> <td>Interstitial lung disease, epidermolysis bullosa</td> <td><a href="https://www.omim.org/entry/614748" target="_blank">#614748</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/601925" target="_blank">ARHGDIA</a></em></td> <td>Rho-GDP dissociation inhibitor alpha</td> <td>DMS</td> <td>Intellectual disability</td> <td><a href="https://www.omim.org/entry/615244" target="_blank">#615244</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/603729" target="_blank">SGPL1</a></em></td> <td>Sphingosine-1-phosphate lyase-1</td> <td>FSGS</td> <td>RENI syndrome – Primary adrenal insufficiency, cryptorchidism, hypothyroidism, neurologic symptoms<sup>[6]</sup></td> <td><a href="https://www.omim.org/entry/617575" target="_blank">#617575</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/610982">INF2</a> </em>(AD)</td> <td>Inverted formin 2</td> <td>FSGS</td> <td>Charcot-Marie-Tooth – Neuropathy and deafness</td> <td><a href="https://www.omim.org/entry/614455" target="_blank">#614455</a></td> </tr> <tr> <td class="subtitle2_left" colspan="5">Mitochondrial podocytopathies</td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/615567" target="_blank">COQ8B</a></em></td> <td>aarF domain-containing kinase 4</td> <td>FSGS (collapsing)</td> <td>CoQ10 deficiency</td> <td><a href="https://www.omim.org/entry/615573" target="_blank">#615573</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/614647" target="_blank">COQ6</a></em></td> <td>Coenzyme Q10 biosynthesis mono-oxygenase 6</td> <td>FSGS or DMS</td> <td>Seizures and sensorineural deafness</td> <td><a href="https://www.omim.org/entry/614650" target="_blank">#614650</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/609825" target="_blank">COQ2</a></em></td> <td>Coenzyme Q10 biosynthesis mono-oxygenase 2</td> <td>FSGS</td> <td>Seizures, hypotonia, lactic acidosis, encephalomyopathy</td> <td><a href="https://www.omim.org/entry/607426" target="_blank">#607426</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/590050" target="_blank">MTTL1</a></em></td> <td>Mitochondrial tRNA<sup>Leu(UUR)</sup></td> <td>FSGS</td> <td> <p>MELAS – Myopathy, encephalopathy, lactic acidosis, stroke-like episode</p> Some individuals have diabetes and deafness</td> <td><a href="https://www.omim.org/entry/540000" target="_blank">#540000</a></td> </tr> <tr> <td class="indent1"><em><a href="https://www.omim.org/entry/610564" target="_blank">PDSS2</a></em></td> <td>Decaprenyl diphosphate synthase subunit 2</td> <td>Renal histology not described</td> <td>Growth retardation, ataxia, deafness</td> <td><a href="https://www.omim.org/entry/614652" target="_blank">#614652</a></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table lists most of the genes that have been associated with SRNS. A few other genes have been identified in case reports; a full list of the genetic heterogeneity of nephrotic syndrome is available <a href="https://www.omim.org/entry/256300" target="_blank">on the MIM website</a>.</div><div class="graphic_footnotes">DMS: diffuse mesangial sclerosis; ESRD: end-stage renal disease; FSGS: focal segmental glomerulosclerosis; n/a: not available; MPGN: membranoproliferative glomerulonephritis; RENI: renal, endocrine, neurologic, and immune syndrome; RNA: ribonucleic acid; SRNS: steroid-resistant nephrotic syndrome.</div><div class="graphic_reference"><p>Original figure modified for this publication. Reproduced from: Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet 2018; 392:61. Table used with the permission of Elsevier Inc. All rights reserved.</p>
References:
<ol>
<li>Ozaltin F, Li B, Rauhauser A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013; 24:377.</li>
<li>Gee HY, Ashraf S, Wan X, et al. Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet 2014; 94:884.</li>
<li>Bierzynska A, Soderquest K, Dean P, et al. MAGI2 mutations cause congenital nephrotic syndrome. J Am Soc Nephrol 2017; 28:1614.</li>
<li>Braun DA, Sadowski CE, Kohl S, et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet 2016; 48:457.</li>
<li>Braun DA, Lovric S, Schapiro D, et al. Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome. J Clin Invest 2018; 128:4313.</li>
<li>Lovric S, Goncalves S, Gee HY, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest 2017; 127:912.</li>
</ol></div><div id="graphicVersion">Graphic 119082 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
